Abstract
Abstract This study explores biosensor technology, focusing on its application in drug detection through advanced quantitative analysis methods: partial least squares (PLS) and probabilistic principal component analysis (PPCA). We developed a rapid quantitative calibration model using azure A, B, and C—metabolites of pefloxacin mesylate and methylene blue— demonstrated through surface-enhanced Raman spectroscopy. The findings highlight the superior accuracy of PLS and PPCA in predicting drug concentrations, with pefloxacin mesylate detection deviations maintained between 0.24%-0.98% and 0.35%-1.02%, respectively. PLS proved to be slightly more effective. This study confirms the potential of biosensor technology in ensuring drug safety, offering substantial support for public health protection and regulatory compliance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
